Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have been given an average recommendation of “Buy” by the eleven analysts that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and seven have assigned a buy recommendation to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $76.43.
KYMR has been the subject of a number of research analyst reports. Zacks Investment Research cut Kymera Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, August 11th. Stifel Nicolaus assumed coverage on shares of Kymera Therapeutics in a research note on Wednesday, September 29th. They issued a “buy” rating and a $80.00 price target on the stock. Bank of America lowered Kymera Therapeutics from a “buy” rating to a “neutral” rating and boosted their target price for the stock from $65.00 to $80.00 in a report on Friday, September 10th. Brookline Capital Acquisition started coverage on Kymera Therapeutics in a research note on Wednesday. They issued a “buy” rating and a $80.00 price target for the company. Finally, Morgan Stanley cut their price target on shares of Kymera Therapeutics from $69.00 to $68.00 and set an “equal weight” rating for the company in a report on Wednesday, August 18th.
KYMR opened at $53.69 on Monday. The company has a fifty day moving average price of $59.35 and a two-hundred day moving average price of $50.92. The firm has a market capitalization of $2.74 billion, a PE ratio of -35.32 and a beta of 1.49. Kymera Therapeutics has a 52 week low of $29.93 and a 52 week high of $91.92.
In related news, Director Bruce Booth sold 242,133 shares of the firm’s stock in a transaction dated Wednesday, August 11th. The shares were sold at an average price of $61.00, for a total transaction of $14,770,113.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Richard Chesworth sold 54,000 shares of Kymera Therapeutics stock in a transaction that occurred on Tuesday, August 17th. The stock was sold at an average price of $50.37, for a total transaction of $2,719,980.00. Following the completion of the sale, the insider now directly owns 54,000 shares in the company, valued at approximately $2,719,980. The disclosure for this sale can be found here. Insiders sold 431,563 shares of company stock valued at $25,455,181 over the last 90 days. Corporate insiders own 23.28% of the company’s stock.
Several institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC increased its holdings in shares of Kymera Therapeutics by 73.2% in the second quarter. Parametric Portfolio Associates LLC now owns 9,732 shares of the company’s stock worth $472,000 after purchasing an additional 4,114 shares during the period. Wells Fargo & Company MN boosted its stake in shares of Kymera Therapeutics by 60.9% during the second quarter. Wells Fargo & Company MN now owns 1,430 shares of the company’s stock valued at $69,000 after purchasing an additional 541 shares during the period. Woodline Partners LP bought a new stake in Kymera Therapeutics during the 2nd quarter valued at $1,831,000. Sphera Funds Management LTD. boosted its position in Kymera Therapeutics by 5.0% during the 2nd quarter. Sphera Funds Management LTD. now owns 259,895 shares of the company’s stock valued at $12,605,000 after buying an additional 12,368 shares during the period. Finally, Invesco Ltd. bought a new stake in Kymera Therapeutics in the 2nd quarter worth $450,000. 51.99% of the stock is owned by hedge funds and other institutional investors.
About Kymera Therapeutics
Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases.
Featured Story: Understanding dividend yield and dividend payout ratio
Receive News & Ratings for Kymera Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kymera Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.